Placed on Senate Legislative Calendar under General Orders. Calendar No. 42.
The bill directs the Federal Trade Commission (FTC) to study intermediaries in the prescription drug supply chain, with particular focus on pharmacy benefit managers (PBMs), pharmacy services administrative organizations, and merger activity. It requires an interim report within 180 days and a full report within one year to the Judiciary Committees, including findings on PBM practices, competition trends, legal or regulatory enforcement obstacles, and policy recommendations.
Progressives emphasize consumer benefits and stronger enforcement recommendations
Low-cost, oversight-focused bill typically attracts bipartisan backing; few direct mandates to provoke opposition.
The bill directs the Federal Trade Commission (FTC) to study intermediaries in the prescription drug supply chain, with particular focus on pharmacy benefit managers (PBMs), pharmacy services administrative organizations, and merger activity.
It requires an interim report within 180 days and a full report within one year to the Judiciary Committees, including findings on PBM practices, competition trends, legal or regulatory enforcement obstacles, and policy recommendations.
Separately, the FTC must report on complaints and enforcement ability related to sole-source drug manufacturers and propose ways to strengthen enforcement.
Narrow, investigatory scope with limited fiscal impact and nonbinding recommendations raises probability of enactment absent strong industry opposition or scheduling barriers.
How solid the drafting looks.
Progressives emphasize consumer benefits and stronger enforcement recommendations
These are examples from the analysis, not a ranked list of the most-affected groups.
Progressives emphasize consumer benefits and stronger enforcement recommendations
Likely strongly supportive: views this as a targeted oversight step to expose anticompetitive PBM and manufacturer behavior.
Sees FTC study as necessary evidence-building to justify stronger enforcement and legislative reforms to lower drug prices.
Generally favorable but pragmatic: views the bill as a reasonable fact-finding exercise to inform policy.
Wants to avoid duplication, ensure analytical rigor, and see cost-benefit analysis before endorsing major interventions.
Skeptical: sees a federal study of market intermediaries as a step toward expanded regulation and intervention.
Accepts a narrow, nonbinding study if it protects proprietary data and avoids recommending heavy-handed market controls.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
Narrow, investigatory scope with limited fiscal impact and nonbinding recommendations raises probability of enactment absent strong industry opposition or scheduling barriers.
The bill has not accumulated any surfaced votes yet.
Progressives emphasize consumer benefits and stronger enforcement recommendations
Narrow, investigatory scope with limited fiscal impact and nonbinding recommendations raises probability of enactment absent strong industr…
Pro readers get the full perspective split, passage barriers, legislative design review, stakeholder impact map, and lens-based policy tradeoff analysis for Prescription Pricing for the People Act of 2025.
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.